Marda Anup 4

What Happened

• Marda Anup, Chief Financial Officer of Cabaletta Bio (CABA), was granted an award/derivative covering 225,000 shares on March 2, 2026. The filing reports an acquisition price of $0.00 (this is a grant of options/awards, not a cash purchase or sale), so no cash changed hands at grant. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-02; reported as a Grant/Award (code A) of a derivative.
• Reported acquisition price: $0.00 (derivative award); not an exercise or sale.
• Vesting (per footnote F1): 25% vests on March 1, 2027; the remainder vests in twelve substantially equal quarterly installments thereafter, subject to continued service.
• Shares owned after transaction: not specified in the provided filing details.
• Filing timeliness: Reported and filed on 2026-03-02 (same date), indicating a timely Form 4.

Context

• This filing documents an option/award grant, not an exercise or sale. The grant vests over time and requires continued employment for vesting; until vested and exercised, the award does not represent immediately tradable shares.
• The Form 4 does not list exercise price or immediate monetary value; such grants are commonly used for executive compensation and retention and should be interpreted as routine compensation unless other insider activity or company events suggest otherwise.